Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.

bioRxiv : the preprint server for biology·2026
Same author

The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Nature cancer·2026
Same journal

Are electrical stimulation devices the way forward for addressing heavy menstrual bleeding in women with von Willebrand disease?

Expert review of hematology·2026
Same journal

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.

Expert review of hematology·2026
Same journal

The impact of a cancer diagnosis for myeloproliferative neoplasm (MPN) patients.

Expert review of hematology·2026
Same journal

Lessons from warfarin management during the COVID-19 pandemic: from crisis to an opportunity to revolutionize telemedicine for chronic disease care.

Expert review of hematology·2026
Same journal

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Expert review of hematology·2026
Same journal

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Expert review of hematology·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Sequential or combination therapy for multiple myeloma.

Ajay Nooka1, Sagar Lonial

  • 1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

Expert Review of Hematology
|November 14, 2012
PubMed
Summary
This summary is machine-generated.

The optimal treatment strategy for myeloma, sequential versus combination therapy, remains unclear. Novel agents necessitate re-evaluating treatment approaches for improved outcomes in multiple myeloma management.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: May 16, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • The optimal therapeutic strategy for multiple myeloma (MM), specifically sequential versus combination therapy, is a long-standing clinical question.
  • Historically, combination cytotoxic chemotherapy showed limited benefit over standard melphalan and prednisone, favoring sequential approaches due to toxicity concerns.
  • Recent advancements in MM treatment include novel agents like immunomodulatory drugs and proteasome inhibitors with improved toxicity profiles, necessitating a re-evaluation of treatment paradigms.

Purpose of the Study:

  • To address the unresolved question of whether sequential or combination therapies are superior in managing multiple myeloma.
  • To investigate the efficacy and safety of different therapeutic strategies in the context of novel agents.
  • To provide evidence-based guidance for optimizing multiple myeloma treatment regimens.

Main Methods:

  • A review of existing literature and clinical trials comparing sequential and combination therapies in multiple myeloma.
  • Analysis of treatment outcomes, including response rates, progression-free survival, and overall survival.
  • Evaluation of toxicity profiles associated with different therapeutic combinations and sequences.

Main Results:

  • Conclusive studies directly comparing sequential and combination therapies in the context of novel agents are lacking.
  • Historical data suggested limited efficacy gains from combination cytotoxic chemotherapy versus sequential approaches.
  • Novel agents offer a new context for re-evaluating the balance between efficacy and toxicity in combination strategies.

Conclusions:

  • The optimal sequencing or combination of novel agents in multiple myeloma requires further rigorous investigation.
  • Re-evaluation of treatment strategies is crucial given the evolving therapeutic landscape and improved patient outcomes.
  • Future research should focus on head-to-head comparisons of sequential versus combination regimens using current standards of care.